|
|
||||
|
New patent strategy succeeds - for now
News from The Scientist 2001, 2(1):20010122-06
|
||||
|
|
||||
|
HOUSTON It seems Bristol-Myers Squibb's novel patent strategy could prove effective in protecting its marketing exclusivity for the blockbuster anxiety drug BuSpar, even though its patent on the drug has expired.
|
|
|||||||||
|
|||||||||
|